ArticleNeurology and therapy2026
Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World Study.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder of the peripheral nervous system. While some patients with CIDP respond to standard-of-care treatments, a significant proportion remains refractory or has partial response. Evidence on the disease burden of this patient group is limited. This retrospective study aimed to analyze the demographics, clinical characteristics, and healthcare resource use of patients with CIDP in the United States, focusing on those who switched therapies within 2 years of initiating first-line treatment (LOT1).
methodsIntegrated data from the Optum
resultsThe CIDP cohort included 1942 treated patients (54% male, 75% aged ≥ 50 years). LOT1 included immunoglobulins (43%), corticosteroids (32%), combination of immunoglobulins and corticosteroids (11%), immunosuppressants (10%), and plasma exchange (5%). Within 2 years, 31% patients switched to second-line treatment (LOT2). The median time to switch from LOT1 to LOT2 was 5.6 months. Within 2 years after initiating LOT1, 92% patients had outpatient visits and 40% were hospitalized. Patients who switched treatments had more healthcare visits than those who did not switch (45.3 vs. 35.3/year).
conclusionApproximately one-third of the patients switched to a new treatment within 2 years after starting treatment, which could be partly due to limited efficacy of therapies in LOT1. The decrease in treatment duration after LOT1 may suggest limited utility of subsequent therapies. Frequent treatment changes and increased healthcare encounters in this subgroup highlight significant unmet needs in CIDP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.